Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017 22:00:00
Aldexa Therap (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
6,45 -0,77 -0,05 71 151
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.12.2017
Popis společnosti
Obecné informace
Název společnostiAldeyra Therapeutics Inc
TickerALDX
Kmenové akcie:Ordinary Shares
RICALDX.O
ISINUS01438T1060
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2014 6
Akcie v oběhu k 9.11.2017 19 117 676
MěnaUSD
Kontaktní informace
Ulice131 Hartwell Ave Ste 320
MěstoLEXINGTON
PSČ02421-3105
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 817 614 904
Fax13026365454

Business Summary: Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 10% to $15.4M. Higher net loss reflects Research and development increase of 11% to $10.8M (expense), General and administrative increase of 9% to $4.7M (expense), Interest Exp-Net of Capitalized Interest increase of 2% to $81K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 17.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorTodd Brady4623.1.201223.1.2012
Chief Financial Officer, TreasurerStephen Tulipano5523.6.201423.6.2014
Chief Operating OfficerScott Young51
Chief Medical OfficerDavid Clark-11.1.201611.1.2016